Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Zvi Steinberg who wrote (649)	4/23/1998 3:58:00 PM
From: Zvi Steinberg	Respond to of 1491

Here's a link to Neuroinvest post (identical to the one at Yahoo) on the IPIC thread on SI FYI: www2.techstocks.com Zvi

To: Zvi Steinberg who wrote (649)	4/24/1998 5:05:00 AM
From: Merav	Respond to of 1491

Pharmos brain drug completely different than Interneuron drug, and Pharmos VP explains why it is likely much better: " Recently, we have received a number of questions concerning the impact of the recent failure of Interneuron's CerAxon in a stroke clinical trial in relation to Pharmos' stroke and head trauma drug, dexanabinol.Although the two drugs are designed to treat the same indication, they differ greatly in their mechanism of action. While CerAxon is involved in the neuronal regeneration process by providing cell membrane building units, Pharmos' dexanabinol is a neuroprotective agent designed to halt the neuronal loss following brain damage. "Dexanabinol holds a unique position among putative neuroprotective agents, since it combines NMDA blocking activity with TNFa inhibitory and anti-oxidant activities in one molecule," said Pharmos Vice President of Research and Development, Dr. Anat Biegon. "This combination of mechanisms of action allows the compound to effectively stop the spreading of brain damage in conditions of stroke and head trauma." The drug demonstrated significant neuroprotective activity in all the relevant animal models and is currently being tested in an advanced PhaseII clinical trail conducted in severe head trauma patients. The Phase II trial protocol was carefully reviewed to assure that the clinical endpoints would provide a solid basis for measurable evidence of dexanabinol's efficacy. Sixty-seven patients have been enrolled so far with no apparent safety concerns (an external safety committee is monitoring the study). The overall mortality in the study is 12.5%, which is relatively low considering the patient population (severe head trauma GCS 4 to 8)." This is from the What's New section of the Pharmos website. (www.pharmoscorp.com)